Parallel Phase II Clinical Trials of Selinexor in Patients With Advanced Thymoma and Thymic Carcinoma
Selinexor demonstrated modest anticancer activity in patients with pretreated advanced TETs. The treatment was complicated by high rates of TRAEs, leading to frequent dose reductions and interruptions.
Authors
- Benjamin Besse (ORCID: https://orcid.org/0000-0001-5090-8189)
- Giuseppe Giaccone
- Gedske Daugaard (ORCID: https://orcid.org/0000-0002-9618-9180)
- René Horsleben Petersen (ORCID: https://orcid.org/0000-0002-3586-1869)
- Vanya Aggarwal (ORCID: https://orcid.org/0000-0001-5387-2193)
- Nicolas M Girard (ORCID: https://orcid.org/0000-0001-9909-2299)
- Jaeil Ahn (ORCID: https://orcid.org/0000-0001-7998-4759)
- Chul Kim (ORCID: https://orcid.org/0000-0003-0191-8684)
- Tianzhi Tang
Institutions
- Georgetown University (US)
- Cornell University (US)
- Université Paris-Saclay (FR)
- Georgetown University Medical Center (US)
- Institut Gustave Roussy (FR)
- Copenhagen University Hospital (DK)
- Rigshospitalet (DK)
- Weill Cornell Medicine (US)
- Institut Curie (FR)
Publication Details
- Journal
- JTO Clinical and Research Reports
- Published
- 2025-05-15
- DOI
- https://doi.org/10.1016/j.jtocrr.2025.100848
- Primary Topic
- Biotin and Related Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00